Phase 2 N=48 Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Metastatic Melanoma
Primary: Number of Participants With Adverse Events — 30; 10; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=807 Web-based Interpretation Training For Anxiety
Anxiety
Primary: Change in Recognition Ratings (Positive Interpretation Bias) — 1.23; 1.19; 1.22; 1.16 score on a scale — p=0.005
Phase 2 N=55 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
Vitiligo
Primary: Change From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48 — 6.58; 6.87; -3.43; -3.46 scores on a scale
Phase 4 N=50 Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis
Idiopathic Scoliosis · Post-operative Pain
Primary: Patient Satisfaction — 2.75; 2.92; 3.31; 3.13 score on a scale
Phase 4 N=334 A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
Actinic Keratosis
Primary: Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9) Total Score of Each Components at Day 57 — 73.64; 82.81; 76.94 score on a scale
N/A N=113 Improving Quality of Life After Thoracic Surgery Using Patient-Reported Outcomes
Thoracic Surgery
Primary: Quality of Life at 12 Months — 80.97; 84.02 units on a scale
Phase 2 N=55 Intravenous Infusion of CAP-1002 in Patients With COVID-19
Covid19
Primary: Safety of CAP-1002: Incidence of All-Cause Mortality — 5; 6 Participants
N/A N=33 RAAS and Arterial Stiffness in SCI
Arterial Stiffness · Renin Angiotensin Aldosterone System · Orthostatic Hypotension
Primary: Pulse Wave Velocity (m/s) — 8.81; 7.36; 5.53 m/s
N/A N=46 Optimizing Self-management COPD Treatment Through the American Lung Association Helpline
Copd
Primary: Health-related Quality of Life — 0.6; 0.7; 1.3; 0.1 score on a scale
N/A N=10 Developing a Mobile Intervention to Reduce Suicidal Cognitions in Veterans
Suicide
Primary: Number of Participants Recruited — 10 Participants
Phase 3 N=526 A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -0.93; -0.71 Percentage of HbA1c — p=<0.0001
Phase 3 N=285 Efficacy and Safety of VVZ-149 Injections in Patients Undergoing Laparoscopic Colectomy
Pain, Postoperative · Acute Pain
Primary: Time-weighted Sum of Pain Intensity Differences for 12 Hours Post-dose (SPID 12) — 26.83; 19.89 score on a scale*hours — p=0.0047
N/A N=34 danceSing Care Evaluation: Testing the Effectiveness
Older Adults · Healthy Aging · Aging
Primary: Change From Baseline Salivary Cortisol Levels — -0.1 micrograms per deciliter — p=.41
Phase 2 N=518 Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults
Influenza, Human
Primary: Hemagglutination-inhibiting (HI) Antibody Titers Against Vaccine-homologous H5N8 — 117.5; 175.2; 121.8; 176.6 Titer
Phase 3 N=1,007 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Gastric Cancer · Gastroesophageal Junction Cancer
Primary: Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms — 44.4; 25.7 Months…